ALBANY, New York, August 30, 2012 /PRNewswire/ --
Twease.org - New Report Added in Biotechnology Reports Database Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics
Mabs" and molecular tests are among the growth industries of pharmaceuticals and diagnostics, but they may have competition long-term from an unexpected source. Epigenomics is a potential game-changer in the clinical therapeutics market and significant in testing as well. It refers to technologies involving changes in genetic material that find their origins in causes other than base pairs alterations in the DNA of the host. Examples of such changes include DNA methylation and histone acetylation, both of which have been known for many years to cause changes in gene expression. This report Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics describes the progress that has been made in our understanding of the basic science of epigenomics and considers the practical accomplishments being reported by the private sector.
Epigenomics constitutes a challenge to the long held paradigm of DNA base pair sequences as the prime determinant of the phenotype. Because of this profound intellectual shift, a vast new area of biological investigation is rapidly unfolding. This presents significant opportunities for understanding disease processes and developing the means of combating them.
Epigenomic Mechanisms Discussed in the report include:
- DNA methylation
- Histone Acetylation
- Histone Phosphorylation
- Histone "chaperones"
- MicroRNAs (miRNAs)
The examination of many diseases in a completely new light means there exist a wealth of opportunities to develop new diagnostic and therapeutic approaches. At the same time it means that outdated concepts will have to be revised. This report looks at the science behind epigenomics and deals with opportunities for product development based on epigenetic technologies and the outlook for the future in this exciting area of pharmaceutical technologies. In doing so, the report provides:
- Discussion of the Basic Science and Mechanisms Behind Epigenomics
- Activities of Top Companies in the Market
- Interviews with Researchers and Private Sector Leaders
- Market Estimates for Current Epigenomic Drugs and Forecast to 2017
- Market Estimates for Current Epigenomic Diagnostics and Comparison to Next Gen Cancer Diagnostics Market
- Analyst Conclusions Regarding the Future Market for Epigenomics
- Key Healthcare Segments Impacted by Epigenomics
- Examples of Clinically Relevant Epigenetic Biomarkers
- Currently Approved Epigenomic Drugs
- Epigenetic Drivers of Disease
- Pharmaceutical R&D: A Need for Better Returns
- Look at Applications in Alzheimer's Disease, Mental Illness, Auto-Immune Diseases, Autism and Cardiovascular Disease
The report strives to predict the potential for epigenomics while reminding market-watchers of the challenges and possible limiting factors in this market. As the report states:
"In the examination of Google hits for "Epigenomics," the phrases "exciting", "state of the art", "cutting edge", "innovative", "breakthrough" and other clichés are encountered over and over. These terms are frequently employed to cover up ideas, concepts and scientific discoveries that may NOT be cutting edge or state of the art and may be past their time, or may never have reached their time. For this reason the report will consider which of these technologies have value and may be ripe for exploitation."
The study of epigenomics today finds itself at a tuningpoint, with many unanswered questions and a proliferation of opportunities forproducts based on the constant flow of new research findings. This report is essential for pharmaceutical and diagnostic marketers looking to develop future business plans and determine opportunities in a promising field.
Twease.org is the number one stop for all the latest reports, news and industry information related to pharmaceutical domain. Our database represents a collection which is updated on a daily basis and consists of all major pharmaceutical market research publishers.